What is the appropriate mometasone furoate nasal spray prescription regimen for a patient with eustachian‑tube salpingitis?

Mometasone Nasal Spray for Eustachian Tube Dysfunction

For eustachian tube dysfunction (salpingitis), prescribe mometasone furoate nasal spray 200 mcg (2 sprays per nostril) once daily, though the evidence supporting its efficacy for this specific indication is weak and conflicting.

Evidence Assessment and Clinical Reality

The available evidence for intranasal corticosteroids in eustachian tube dysfunction presents a mixed picture:

Supporting Evidence

• A 2020 prospective study 1 demonstrated that allergic rhinitis patients with eustachian tube dysfunction showed significant improvement in ETDQ-7 scores and tubomanometry measurements after 1 month of mometasone furoate nasal spray treatment (p < 0.0001)
• A 2025 pediatric study 2 in secretory otitis media (related to eustachian tube dysfunction) showed 92.11% effectiveness with mometasone furoate nasal spray over 12 weeks, with improved T-ETDQ scores and hearing outcomes

Contradicting Evidence

• A 2024 systematic review and meta-analysis 3 of randomized controlled trials (n=512 ears) found no significant difference in tympanometric normalization between intranasal corticosteroids and control (OR 1.21,95% CI 0.65-2.24)
• A 2023 prospective controlled study 4 showed no significant improvement in otitis media with effusion at 2 weeks with mometasone furoate versus saline (p > 0.05)
• The 2016 AAO-HNS guideline 5 provides a strong recommendation against using intranasal steroids for otitis media with effusion (which shares pathophysiology with eustachian tube dysfunction)

Practical Prescribing Regimen

Despite weak evidence, if you choose to prescribe based on the inflammatory component:

Standard Dosing:

• Adults and children ≥12 years: 2 sprays (100 mcg total) per nostril once daily 6
• Children 2-11 years: 1 spray (50 mcg) per nostril once daily 7
• Duration: Trial for 4-8 weeks minimum before assessing efficacy 1

Administration technique (critical for efficacy):

• Shake bottle well before each use
• Aim spray away from nasal septum (toward outer wall of nose)
• Prime pump if new bottle or unused for >1 week 7
• Use consistently at same time daily for optimal effect

Clinical Algorithm for Decision-Making

Consider mometasone furoate nasal spray when:

1. Eustachian tube dysfunction is associated with allergic rhinitis or chronic rhinosinusitis (strongest rationale) 1
2. Significant nasal obstruction is present (VAS scores correlate with ETDQ-7 scores, r=0.5124) 1
3. Inflammatory changes visible at pharyngeal orifice of eustachian tube on nasal endoscopy 1

Do NOT use when:

1. Isolated eustachian tube dysfunction without nasal inflammatory disease 5
2. Acute otitis media with effusion in children (strong recommendation against) 5
3. Expected short-term resolution (<3 months) 5

Important Caveats

• The 2008 Rhinitis guideline 8 supports topical decongestants for eustachian tube dysfunction, not intranasal corticosteroids specifically, though it notes decongestants should be limited to short-term use (3-7 days maximum) to avoid rhinitis medicamentosa
• The mechanism of benefit, when present, appears related to reducing inflammation at the nasopharyngeal opening of the eustachian tube rather than direct tube effects 1
• Combination therapy may be more appropriate: Consider adding oral antihistamine (loratadine) if allergic component present, as this combination showed significant improvement in the 2020 study 1
• Monitor for local adverse effects: epistaxis, nasal irritation, septal ulceration (examine septum periodically) 6
• In children, use lowest effective dose and avoid long-term continuous use without periodic reassessment 6

Bottom Line

The evidence does not strongly support intranasal corticosteroids for isolated eustachian tube dysfunction, and current AAO-HNS guidelines recommend against their use in related conditions like otitis media with effusion 5, 3. However, when eustachian tube dysfunction occurs in the context of allergic rhinitis or chronic rhinosinusitis with demonstrable nasal inflammation, a trial of mometasone furoate 200 mcg daily for 4-8 weeks is reasonable, with the understanding that efficacy is uncertain and should be reassessed if no improvement occurs.